RhumbLine Advisers’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.11M Buy
160,569
+2,473
+2% +$104K ﹤0.01% 1312
2026
Q2
$7.44M Buy
158,096
+38,124
+32% +$942K 0.01% 1259
2026
Q1
$2.27M Buy
119,972
+9,225
+8% +$157K ﹤0.01% 1779
2025
Q4
$1.48M Sell
110,747
-1,371
-1% -$17K ﹤0.01% 2034
2025
Q3
$1.32M Sell
112,118
-3,178
-3% -$29.6K ﹤0.01% 2103
2025
Q2
$748K Buy
115,296
+6,839
+6% +$45K ﹤0.01% 2402
2025
Q1
$634K Buy
108,457
+7,762
+8% +$55.6K ﹤0.01% 2415
2024
Q4
$701K Buy
100,695
+4,868
+5% +$33.5K ﹤0.01% 2454
2024
Q3
$545K Buy
95,827
+1,711
+2% +$11.9K ﹤0.01% 2645
2024
Q2
$679K Buy
+94,116
New +$823K ﹤0.01% 2460
2022
Q2
– Sell
-20,112
Closed -$335K – 3185
2022
Q1
$335K Sell
20,112
-551
-3% -$9.6K ﹤0.01% 2602
2021
Q4
$428K Buy
20,663
+183
+0.9% +$5.84K ﹤0.01% 2574
2021
Q3
$716K Buy
20,480
+992
+5% +$42.9K ﹤0.01% 2383
2021
Q2
$1.01M Buy
+19,488
New +$1.02M ﹤0.01% 2243

Other funds holding DFTX

RhumbLine Advisers's DFTX Position: Q3 2026 in Review

RhumbLine Advisers increased its Definium Therapeutics (DFTX) stake by 1.6% in Q3 2026, buying an estimated $104K and bringing the position to 160,569 shares worth $6.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

RhumbLine Advisers first reported a position in DFTX in Q2 2021 and has held it in 14 quarters since. The position peaked at $7.44M in Q2 2026. 349 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • RhumbLine Advisers held 160,569 shares of Definium Therapeutics worth $6.11M as of Q3 2026.
  • RhumbLine Advisers bought 2,473 Definium Therapeutics shares in Q3 2026, an estimated $104K.
  • Definium Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1312 holding.
  • RhumbLine Advisers first reported a position in Definium Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • RhumbLine Advisers's Definium Therapeutics position peaked at $7.44M in Q2 2026.
  • 349 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.